{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:35Z","timestamp":1791563135559,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigate the association between frequency of comorbidities and number of concomitantly prescribed medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Administrative claims data were obtained from the IBM\u00ae MarketScan\u00ae database for a cohort of patients with acromegaly, identified by relevant diagnosis codes and acromegaly treatments, and a matched control cohort of patients without acromegaly from January 2010 through April 2020. Comorbidities were identified based on relevant claims and assessed for both cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1175 patients with acromegaly and 5875 matched patients without acromegaly were included. Patients with acromegaly had significantly more comorbidities and were prescribed concomitant medications more so than patients without acromegaly. In the acromegaly and control cohorts, respectively, 67.6% and 48.4% of patients had cardiovascular disorders, the most prevalent comorbidities, and 89.0% and 68.3% were prescribed\u2009&gt;\u20093 concomitant medications (p\u2009&lt;\u20090.0001). Hypopituitarism and hypothalamic disorders, sleep apnea, malignant neoplasms and cancer, and arthritis and musculoskeletal disorders were also highly prevalent in the acromegaly cohort. A moderate, positive correlation (Spearman correlation coefficient 0.60) was found between number of comorbidities and number of concomitant medications in the acromegaly cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared with patients without acromegaly, patients with acromegaly have significantly more comorbidities and are prescribed significantly more concomitant medications. Physicians should consider the number and type of ongoing medications for individual patients before prescribing additional acromegaly treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-021-01198-5","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T07:16:29Z","timestamp":1641021389000},"page":"296-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"del Pilar Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Darhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amicie","family":"de Pierrefeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Antonio","family":"Ribeiro-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Neggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"issue":"Suppl 1","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"A649","DOI":"10.1210\/jendso\/bvab048.1324","volume":"5","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Barkan A, del Schneider MP, Darhi Y, de Pierrefeu A, Munoz K, Ribeiro-Oliveira A, Melmed S (2021) The pharmacological burden of comorbidities in acromegaly. J Endocr Soc 5(Suppl 1):A649\u2013A650. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1324","journal-title":"J Endocr Soc"},{"issue":"11","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH (2014) Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1198_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382(10):937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"issue":"9","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"577173","DOI":"10.3389\/fendo.2020.577173","volume":"11","author":"G Vila","year":"2020","unstructured":"Vila G, Luger A, van der Lely AJ, Neggers S, Webb SM, Biller BMK, Valluri S, Hey-Hadavi J (2020) Hypertension in acromegaly in relationship to biochemical control and mortality: global ACROSTUDY outcomes. Front Endocrinol (Lausanne) 11:577173. https:\/\/doi.org\/10.3389\/fendo.2020.577173","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1198_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","volume":"20","author":"A Lavrentaki","year":"2017","unstructured":"Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N (2017) Epidemiology of acromegaly: review of population studies. Pituitary 20(1):4\u20139. https:\/\/doi.org\/10.1007\/s11102-016-0754-x","journal-title":"Pituitary"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/ijgm.S169611","volume":"11","author":"S AlDallal","year":"2018","unstructured":"AlDallal S (2018) Acromegaly: a challenging condition to diagnose. Int J Gen Med 11:337\u2013343. https:\/\/doi.org\/10.2147\/ijgm.S169611","journal-title":"Int J Gen Med"},{"issue":"1","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13023-016-0516-x","volume":"11","author":"T Brue","year":"2016","unstructured":"Brue T, Castinetti F (2016) The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis 11(1):135. https:\/\/doi.org\/10.1186\/s13023-016-0516-x","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1198_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060041","volume":"8","author":"JF Mart\u00edn-Rodr\u00edguez","year":"2013","unstructured":"Mart\u00edn-Rodr\u00edguez JF, Madrazo-Atutxa A, Venegas-Moreno E, Benito-L\u00f3pez P, G\u00e1lvez M\u00c1, Cano DA, Tinahones FJ, Torres-Vela E, Soto-Moreno A, Leal-Cerro A (2013) Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus na\u00efve acromegaly. PLoS ONE 8(4):e60041. https:\/\/doi.org\/10.1371\/journal.pone.0060041","journal-title":"PLoS ONE"},{"issue":"1","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93(1):61\u201367. https:\/\/doi.org\/10.1210\/jc.2007-1191","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1198_CR11","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1210\/jc.2002-021099","volume":"88","author":"A Colao","year":"2003","unstructured":"Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G (2003) High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case\u2013control study. J Clin Endocrinol Metab 88(7):3196\u20133201. https:\/\/doi.org\/10.1210\/jc.2002-021099","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1198_CR12","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/jci39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Investig 119(11):3189\u20133202. https:\/\/doi.org\/10.1172\/jci39375","journal-title":"J Clin Investig"},{"issue":"1","key":"1198_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332. https:\/\/doi.org\/10.1210\/er.2018-00115","journal-title":"Endocr Rev"},{"issue":"3","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/eje-07-0697","volume":"158","author":"MP Matta","year":"2008","unstructured":"Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH\/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305\u2013310. https:\/\/doi.org\/10.1530\/eje-07-0697","journal-title":"Eur J Endocrinol"},{"key":"1198_CR15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000375163","volume":"103","author":"J McCabe","year":"2016","unstructured":"McCabe J, Ayuk J, Sherlock M (2016) Treatment factors that influence mortality in acromegaly. Neuroendocrinology 103(1):66\u201374. https:\/\/doi.org\/10.1159\/000375163","journal-title":"Neuroendocrinology"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"101389","DOI":"10.1016\/j.ghir.2021.101389","volume":"59","author":"M Whittington","year":"2021","unstructured":"Whittington M, Munoz K, Whalen J, Ribeiro-Oliveira A Jr, Campbell J (2021) Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm IGF Res 59:101389. https:\/\/doi.org\/10.1016\/j.ghir.2021.101389","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"1198_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"issue":"3","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11102-012-0432-6","volume":"16","author":"T Burton","year":"2013","unstructured":"Burton T, Le Nestour E, Bancroft T, Neary M (2013) Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary 16(3):354\u2013362. https:\/\/doi.org\/10.1007\/s11102-012-0432-6","journal-title":"Pituitary"},{"issue":"12","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"R274","DOI":"10.1530\/EC-20-0433","volume":"9","author":"B Maia","year":"2020","unstructured":"Maia B, Kasuki L, Gadelha MR (2020) Novel therapies for acromegaly. Endocr Connect 9(12):R274\u2013R285. https:\/\/doi.org\/10.1530\/EC-20-0433","journal-title":"Endocr Connect"},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ppa.s54922","volume":"8","author":"M Sabbatini","year":"2014","unstructured":"Sabbatini M, Garofalo G, Borrelli S, Vitale S, Torino M, Capone D, Russo L, Pisani A, Carrano R, Gallo R, Federico S (2014) Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence 8:73\u201381. https:\/\/doi.org\/10.2147\/ppa.s54922","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1198_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2337\/diaclin.33.2.55","volume":"33","author":"M Bl\u00fcher","year":"2015","unstructured":"Bl\u00fcher M, Kurz I, Dannenmaier S, Dworak M (2015) Pill burden in patients with type 2 diabetes in Germany: subanalysis from the prospective, noninterventional PROVIL study. Clin Diabetes 33(2):55. https:\/\/doi.org\/10.2337\/diaclin.33.2.55","journal-title":"Clin Diabetes"},{"issue":"5","key":"1198_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1715163513500208","volume":"146","author":"B Farrell","year":"2013","unstructured":"Farrell B, French Merkley V, Ingar N (2013) Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J 146(5):262\u2013269. https:\/\/doi.org\/10.1177\/1715163513500208","journal-title":"Can Pharm J"},{"issue":"2","key":"1198_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010035","volume":"6","author":"MA Mohammed","year":"2016","unstructured":"Mohammed MA, Moles RJ, Chen TF (2016) Medication-related burden and patients\u2019 lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open 6(2):e010035. https:\/\/doi.org\/10.1136\/bmjopen-2015-010035","journal-title":"BMJ Open"},{"issue":"1","key":"1198_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.15256\/joc.2018.8.119","volume":"8","author":"T van Merode","year":"2018","unstructured":"van Merode T, van de Ven K, van den Akker M (2018) Patients with multimorbidity and their treatment burden in different daily life domains: a qualitative study in primary care in the Netherlands and Belgium. J Comorbidity 8(1):9\u201315. https:\/\/doi.org\/10.15256\/joc.2018.8.119","journal-title":"J Comorbidity"},{"issue":"4","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4103\/picr.PICR_132_16","volume":"8","author":"A Khandeparkar","year":"2017","unstructured":"Khandeparkar A, Rataboli PV (2017) A study of harmful drug\u2013drug interactions due to polypharmacy in hospitalized patients in Goa Medical College. Perspect Clin Res 8(4):180\u2013186. https:\/\/doi.org\/10.4103\/picr.PICR_132_16","journal-title":"Perspect Clin Res"},{"issue":"3","key":"1198_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3851\/imp1540","volume":"15","author":"C Marzolini","year":"2010","unstructured":"Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave J-P, Cavassini M, Bernasconi E, Calmy A (2010) Prevalence of comedications and effect of potential drug\u2013drug interactions in the Swiss HIV Cohort Study. Antivir Ther 15(3):413. https:\/\/doi.org\/10.3851\/imp1540","journal-title":"Antivir Ther"},{"issue":"3","key":"1198_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","volume":"11","author":"B Homayun","year":"2019","unstructured":"Homayun B, Lin X, Choi H-J (2019) Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 11(3):129. https:\/\/doi.org\/10.3390\/pharmaceutics11030129","journal-title":"Pharmaceutics"},{"issue":"1","key":"1198_CR29","doi-asserted-by":"publisher","first-page":"9613","DOI":"10.1038\/s41598-017-10110-w","volume":"7","author":"H Kim","year":"2017","unstructured":"Kim H, Park H, Lee SJ (2017) Effective method for drug injection into subcutaneous tissue. Sci Rep 7(1):9613\u20139613. https:\/\/doi.org\/10.1038\/s41598-017-10110-w","journal-title":"Sci Rep"},{"issue":"6","key":"1198_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"1198_CR31","unstructured":"Python Software Foundation (n.d.) Python language reference. http:\/\/www.python.org. Accessed 7 Dec 2021"},{"key":"1198_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fpubh.2020.00147","volume":"8","author":"M Kamusheva","year":"2020","unstructured":"Kamusheva M, Vandeva S, Mitov K, Rusenova Y, Elenkova A, Zacharieva S, Mitkova Z, Tachkov K, Dimitrova M, Doneva M, Tcharaktchiev D, Petrova G (2020) New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria. Front Public Health 8:147. https:\/\/doi.org\/10.3389\/fpubh.2020.00147","journal-title":"Front Public Health"},{"issue":"10","key":"1198_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, Auriemma R, Diallo AM, Hulting A-L, Ferone D, Hana V Jr, Filipponi S, Sievers C, Nogueira C, Fajardo-Monta\u00f1ana C, Carvalho D, Hana V, Stalla GK, Jaffrain-R\u00e9a M-L, Delemer B, Colao A, Brue T, Neggers SJCMM, Zacharieva S, Chanson P, Beckers A (2017) Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24(10):505\u2013518. https:\/\/doi.org\/10.1530\/ERC-17-0253","journal-title":"Endocr Relat Cancer"},{"issue":"17","key":"1198_CR34","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL (2015) Trends in prescription drug use among adults in the United States From 1999\u20132012. JAMA 314(17):1818\u20131831. https:\/\/doi.org\/10.1001\/jama.2015.13766","journal-title":"JAMA"},{"issue":"2","key":"1198_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5001\/omj.2011.21","volume":"26","author":"R Bushra","year":"2011","unstructured":"Bushra R, Aslam N, Khan AY (2011) Food\u2013drug interactions. Oman Med J 26(2):77\u201383. https:\/\/doi.org\/10.5001\/omj.2011.21","journal-title":"Oman Med J"},{"key":"1198_CR36","unstructured":"FDA (2008) Prescribing information: glucotrol\u2014glipzide tablet. FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/017783s019lbl.pdf. Accessed 7 Dec 2021"},{"issue":"1","key":"1198_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.17925\/EE.2013.09.01.40","volume":"9","author":"P Colucci","year":"2013","unstructured":"Colucci P, Yue CS, Ducharme M, Benvenga S (2013) A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol 9(1):40\u201347. https:\/\/doi.org\/10.17925\/EE.2013.09.01.40","journal-title":"Eur Endocrinol"},{"issue":"4","key":"1198_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/foods10040720","volume":"10","author":"A Wiesner","year":"2021","unstructured":"Wiesner A, Szuta M, Galanty A, Pa\u015bko P (2021) Optimal dosing regimen of osteoporosis drugs in relation to food intake as the key for the enhancement of the treatment effectiveness\u2014a concise literature review. Foods (Basel Switz) 10(4):720. https:\/\/doi.org\/10.3390\/foods10040720","journal-title":"Foods (Basel Switz)"},{"issue":"4","key":"1198_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"R-S Wedemeyer","year":"2014","unstructured":"Wedemeyer R-S, Blume H (2014) Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 37(4):201\u2013211. https:\/\/doi.org\/10.1007\/s40264-014-0144-0","journal-title":"Drug Saf"},{"key":"1198_CR40","unstructured":"FDA (2020) Highlights of prescribing information. In: MYCAPSSA (octreotide) delayed-release capsules, for oral use. FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208232s000lbl.pdf. Accessed 7 Dec 2021"},{"issue":"1","key":"1198_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","volume":"20","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Liu S, Mathias SD, Gelbaum D, Shi L (2020) Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr Disord 20(1):117. https:\/\/doi.org\/10.1186\/s12902-020-00595-4","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"1198_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","volume":"23","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Crosby RD, Ludlam WH, Haviv A, Mathias SD (2020) An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary 23(4):347\u2013358. https:\/\/doi.org\/10.1007\/s11102-020-01038-y","journal-title":"Pituitary"},{"issue":"2","key":"1198_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2265.2006.02450.x","volume":"64","author":"P Caron","year":"2006","unstructured":"Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64(2):209\u2013214. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02450.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1198_CR44","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1210\/jc.2017-00359","volume":"102","author":"DI Spratt","year":"2017","unstructured":"Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, Spratt LV, Eimicke T, Olshan JS (2017) Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab 102(7):2349\u20132355. https:\/\/doi.org\/10.1210\/jc.2017-00359","journal-title":"J Clin Endocrinol Metab"},{"key":"1198_CR45","unstructured":"NHS (2018) Can small volume intramuscular injections be given to patients taking oral anticoagulants? NHS. https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2018\/09\/UKMI_QA_IM-inj-anticoag_partial-update_Sept2018.pdf. Accessed 7 Dec 2021"},{"issue":"12","key":"1198_CR46","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","volume":"107","author":"J Hirsh","year":"2003","unstructured":"Hirsh J, Fuster V, Ansell J, Halperin JL (2003) American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107(12):1692\u20131711. https:\/\/doi.org\/10.1161\/01.CIR.0000063575.17904.4E","journal-title":"Circulation"},{"issue":"12","key":"1198_CR47","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.amjmed.2019.07.021","volume":"132","author":"JS Alpert","year":"2019","unstructured":"Alpert JS (2019) Take-home messages from the recently updated AHA\/ACC guidelines for atrial fibrillation. Am J Med 132(12):1363\u20131364. https:\/\/doi.org\/10.1016\/j.amjmed.2019.07.021","journal-title":"Am J Med"},{"issue":"5","key":"1198_CR48","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"DJ Kumbhani","year":"2021","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH (2021) 2020 ACC Expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. J Am Coll Cardiol 77(5):629\u2013658. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.011","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"1198_CR49","doi-asserted-by":"publisher","first-page":"A528","DOI":"10.1210\/jendso\/bvab048.1076","volume":"5","author":"S Petersenn","year":"2021","unstructured":"Petersenn S, Houchard A, del Pilar Schneider M, Ribeiro-Oliveira A Jr, Neggers S (2021) Use of oral concomitant medications in patients with acromegaly. J Endocr Soc 5(Suppl 1):A528\u2013A529. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1076","journal-title":"J Endocr Soc"},{"issue":"3","key":"1198_CR50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","volume":"63","author":"T Brue","year":"2019","unstructured":"Brue T, Lindberg A, van der Lely JA, Akerblad AC, Koltowska-H\u00e4ggstr\u00f6m M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, Camacho-H\u00fcbner C (2019) Diabetes in patients with acromegaly treated with pegvisomant: observations from ACROSTUDY. Endocrine 63(3):563\u2013572. https:\/\/doi.org\/10.1007\/s12020-018-1792-0","journal-title":"Endocrine"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01198-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T15:14:06Z","timestamp":1646320446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01198-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]},"assertion":[{"value":"25 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF: Scientific Consultant for Chiasma, Crinetics, Ionis, Ipsen, Pfizer, and Recordati; Principal Investigator with support to the institution for Chiasma, Crinetics, Ionis, and Novartis; on the Editorial Board of <i>Pituitary<\/i>; AB: Editor for <i>Pituitary<\/i>; MdPS: employee of Ipsen; YD: employee of Ipsen; AdP: employee of Ipsen; SP: has been a speaker at workshops and\/or Advisory Board Member for Crinetics, Ipsen, Novartis, Pfizer, Recordati, and Takeda; on the Editorial Board of <i>Pituitary<\/i>; SN: consulting and research fees from Ipsen and Pfizer; consulting fees from Crinetics and Recordati; on the Editorial Board of <i>Pituitary<\/i>; AROJR: employee of Ipsen; SM: consulting fee; Chiasma, Crinetics, Ionis, Ipsen; funding to institution from Pfizer; Editor-in-Chief for <i>Pituitary<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}